Outcome of gastric cancer patients after successful gastrectomy: Influence of the type of recurrence and histology on survival

Cancer

Volumn 107, Issue 11, 2006, Pages 2576-2580

  Rohatgi, Pooja R ^a   Yao, James C ^a   Hess, Kenneth ^a   Schnirer, Isac ^a   Rashid, Asif ^a   Mansfield, Paul F ^a   Pisters, Peter W ^a   Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Distant metastasis; Neoplasms; Stomach; Survival

Indexed keywords

CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; CELL DIFFERENTIATION; FEMALE; GASTRECTOMY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; STOMACH CANCER; TUMOR LOCALIZATION;

FEMALE; GASTRECTOMY; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 33751584094     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22317     Document Type: Review

References (25)

1. Ajani J, Fairweather J, Pisters P, et al. Phase II study of CPT-11 plus cisplatin in patients with advanced gastric and GE junction carcinomas. Cancer. 2002;94:641-646.
2. Baek JH, Kim JG, Jeon SB, et al. Phase II study of canecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer. Br J Cancer. 2006;22:1407-1411.
3. Papakostas P, Tsavdaridis D, Kosmidis P, et al. Combination docetaxel (Taxotere), fluorouracil, and leucovorin (TFL), as first-line chemotherapy in advanced gastric cancer a Hellenic Cooperative Oncology Group phase II study. Gastric Cancer. 2006;9:26-31.
4. Jeung HC, Rha SY, Kim YT, Noh SH, Roh JK, Chung HC. A phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer. Oncology. 2006;70:63-70.
5. Ajani JA, Fodor MB, Tjulandin SA, et al. Phase II multinational randomized trial docetaxtel plus cisplatin with or without 5-fluorouracil in patients (Pts) with advanced gastric or GE junction adenocarcinoma. J Clin Oncol. 2005;23:5600-5667.
6. Ajani JA, Lee FC, Singh DA, et al. Multicenter phase II trial of S-I plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006;24:663-667.
7. Park SH, Lee WK, Chung M, et al. Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil. Anticancer Drugs. 2006;17:225-229.
8. Enzinger PC, Kulke MH, Clark JW, et al. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci. 2005;50:2218-2223.
9. Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist. 2005;10(suppl 3):49-58.
10. Wanebo HJ, Kennedy BJ, Chmiel J, et al. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 1993;218:583-592.
11. Kim JP, Lee JH, Kim SI, et al. Clinicopathologic characteristics and prognostic factors in 10783 patients with gastric cancer. Gastric Cancer. 1998;1:125-133.
12. Talamonti MS, Kim SP, Yao KA, et al. Surgical outcomes of patients with gastric carcinoma: the importance of primary tumor location and microvessel invasion. Surgery. 2003;134:720-727; discussion, 727-729.
13. Macdonald JS. Treatment of localized gastric cancer. Semin Oncol. 2004;31:566-573.
14. Buzzoni R, Bajetta E, Di Bartolomeo M, et al. Pathological features as predictors of recurrence after radical resection of gastric cancer. Br J Surg. 2006;93:205-209.
15. Roukos OH, Kappas AM. Perspectives in the treatment of gastric cancer. Natl Clin Pract Oncol. 2005;2:98-107.
16. Petrioli R, Sabatino M, Roviello F, et al. Folinic acid, 5-fluorouracil and etoposide after curative resection for gastric cancer. Hepatogastroenterology. 2005;52:1626-1630.
17. Persiani R, D'Ugo D, Rausei S, et al. Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy. J Surg Oncol. 2005;89:227-236; discussion, 237-238.
18. Bora H, Unsal D, Akmansu M. Results of chemoirradiation after curative resection of locally advanced gastric cancer. Int J Clin Pract. 2004;58:451-456.
19. Yuasa N, Nimura Y. Survival after surgical treatment of early gastric cancer, surgical techniques, and long-term survival. Langenbecks Arch Surg. 2005;390:286-293.
20. Ajani JA, Ota DM, Jessup JM, et al. Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. Cancer. 1991;68:1501-1506.
21. Crookes P, Leichman CG, Leichman L, et al. Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report. Cancer. 1997;79: 1767-1775.
22. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymphnode dissection for gastric cancer. Dutch Gastric Cancer Group. N Engl J Med. 1999;340:908-914.
23. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 1999;79:1522-1530.
24. Onate-Ocana LF, Aiello-Crocifoglio V, Mondragon-Sanchez R, et al. Survival benefit of D2 lympadenectomy in patients with gastric adenocarcinoma. Ann Surg Oncol. 2000;7:210-217.
25. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-730.